Logo

Michael Korn

Sep 19, 2017

Michael Korn has been appointed the chief medical officer of Caris Life Sciences, where he will guide the firm's research efforts and clinical strategies for the Adapt Biotargeting System and Caris Molecular Intelligence tumor profiling. Korn is a professor of medicine in the division of hematology/concology at the University of California, San Francisco, and he replaces John Marshal, who was CMO for Caris on a part-time basis. Marshall will continue as chairman of the Precision Oncology Alliance, which is powered by Caris.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.